Designer vaccines to prevent infections due to group B Streptococcus

Area of Science:

• Bacteriology
• Immunology
• Vaccinology

Background:

• Group B streptococci (GBS) cause severe neonatal infections and infections in adults, particularly peripartum women and immunocompromised individuals.
• Maternal antibodies to GBS capsular polysaccharides provide passive immunity to neonates, but purified polysaccharides have limited immunogenicity.
• Developing an effective GBS vaccine is crucial for reducing neonatal morbidity and mortality.

Purpose of the Study:

• To develop and evaluate a novel glycoconjugate vaccine against Group B streptococci (GBS).
• To assess the immunogenicity and protective efficacy of the GBS glycoconjugate vaccine in preclinical and early clinical studies.

Main Methods:

• A glycoconjugate vaccine was designed by covalently linking GBS type-specific polysaccharides to tetanus toxoid via a secondary amine linkage.
• Epitope mapping confirmed preservation of key polysaccharide conformational epitopes after periodate oxidation and conjugation.
• Preclinical studies in animal models evaluated vaccine immunogenicity and protective efficacy.
• Phase I clinical trials are assessing the safety and immunogenicity of the GBS glycoconjugate vaccine in humans.

Main Results:

• Preclinical testing in animal models demonstrated that the glycoconjugate vaccine elicits immunogenic and protective antibodies against GBS.
• Early Phase I clinical trial results for the GBS glycoconjugate vaccine are promising, indicating successful antibody generation.

Conclusions:

• The novel GBS glycoconjugate vaccine strategy is a promising approach to induce protective immunity.
• Further clinical evaluation is warranted to confirm the safety and efficacy of this GBS vaccine in preventing neonatal infections.